Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314738 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
A Phase 1 study of Progressive Keratoconus, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT05314738: Recruiting Phase 1 study of Progressive Keratoconus, sponsored by Glaukos Corporation.
NCT05314738 is a Phase 1 study of Progressive Keratoconus that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05314738, a Phase 1 study of Progressive Keratoconus, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NXL Energy 1
- COMBINATION_PRODUCT NXL Energy 2
- COMBINATION_PRODUCT NXL Energy 3
- COMBINATION_PRODUCT Sham Treatment
Study Locations (3)
Alabama
- Glaukos Investigative Site - Dothan
New Jersey
- Glaukos Investigative Site - Teaneck
Ohio
- Glaukos Investigative Site - Westerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
What NCT05314738 shows while recruiting
NCT05314738 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Progressive Keratoconus appearing as the primary indexed condition, and to 4 interventions - of which NXL Energy 1 is the first listed.
NCT05314738 reports a single indexed study location in Alabama, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT05314738 about?
NCT05314738 is a clinical study titled "Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus". Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
What is the current status of trial NCT05314738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-03-08. Estimated completion is 2026-02.
What conditions does trial NCT05314738 study?
This clinical trial studies the following conditions: Progressive Keratoconus.
What interventions are being tested in trial NCT05314738?
The interventions under investigation include: NXL Energy 1 (COMBINATION_PRODUCT), NXL Energy 2 (COMBINATION_PRODUCT), NXL Energy 3 (COMBINATION_PRODUCT), Sham Treatment (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05314738?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05314738 being conducted?
This trial has 3 study locations across Alabama, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05314738's enrollment target sits among peer trials
150 364th of 2000 higher than 1,620 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI